USA, Chicago 
Dr. Nabiel Mir is a clinician-scientist in medical oncology at the University of Chicago, specializing in geriatric oncology and genitourinary cancers, with a focus on digital biomarkers, wearable technologies, and personalized cancer care for older adults.
Current Position
- Instructor (Pathways to Independence), Section of Hematology and Oncology, University of Chicago
- Clinical practice in geriatric oncology and genitourinary oncology
Education
- M.B.B.S., University of Queensland
- B.S., Human Physiology, McGill University
- Residency, Internal Medicine, University of Alabama at Birmingham
- Fellowships in Geriatrics and Hematology & Oncology, University of Chicago
- Postdoctoral training in clinical therapeutics, pharmacology, and pharmacogenomics, University of Chicago
Clinical & Research Focus
- Geriatric oncology and aging-related vulnerability in cancer
- Prostate cancer and genitourinary malignancies
- Digital biomarkers and wearable-derived health data
- Frailty, functional decline, and treatment tolerability
- AI-driven and personalized oncology approaches
Academic Profile
- Author of peer-reviewed publications in digital health, frailty, and oncology
- Active in translational and outcomes research in older adults with cancer
- Contributor to international geriatric oncology efforts
Research Innovation & Programs
Dr. Mir leads several innovative programs integrating digital health into oncology care:
- GeRI (Geriatric Remote Initiative) – an open-source platform for remote symptom tracking and frailty monitoring
- Development of wearable-based biomarkers using accelerometry and real-world data
- Machine learning models for toxicity prediction, including AndroTox
- Clinical research programs such as ProGATE / ProsGATE focused on geriatric assessment in prostate cancer
- DAROSTEP, evaluating digital activity metrics as biomarkers of treatment outcomes
- HeNeFit, exploring digital biomarkers of frailty and resilience in vulnerable cancer populations
Funding & Grants
- Principal Investigator on multiple competitive grants, including a Prostate Cancer Foundation Young Investigator Award
- Research funding across institutional and national programs focused on digital biomarkers and geriatric oncology
- Ongoing and pending projects in the $100K–$1M+ range
Leadership & Contributions
- Contributor to International Society of Geriatric Oncology prostate cancer guidelines
- Collaborator with Digital Medicine Society on digital health initiatives
- Peer reviewer for oncology and digital health journals
- Invited speaker at international oncology and aging conferences
Certifications
- ABIM Internal Medicine
- ABIM Geriatric Medicine
- ABIM Medical Oncology (2025)